2013
DOI: 10.1002/pbc.24648
|View full text |Cite
|
Sign up to set email alerts
|

Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly‐diagnosed with central nervous system atypical teratoid/rhabdoid tumors: The head start III experience

Abstract: A minority of children with CNS AT/RT treated on HS III may be long-term survivors without irradiation. More effective therapies are desperately needed.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
68
0
5

Year Published

2015
2015
2020
2020

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 90 publications
(73 citation statements)
references
References 29 publications
0
68
0
5
Order By: Relevance
“…[13][14][15][16][17][18][19][20][21][22] The basic treatment schema consisted of five 21-to 28-day cycles of induction chemotherapy: cisplatin (3.5 mg/kg) on day 0, vincristine (0.05 mg/kg) on days 0, 8 and 15, cyclophosphamide (65 mg/kg) on days 1 and 2 and etoposide (4 mg/kg) on days 1 and 2 (Regimen A, HS I) with the addition of high-dose methotrexate (400 mg/kg) on day 3 for metastatic patients (HS II Regimen A2), or with two cycles replacing cisplatin and methotrexate by oral etoposide (1.67 mg/kg/day) on days 1-10 and oral temozolomide (6.5 mg/kg/day) on days 1-5 (HS III Regimen D or D2). During HS III, Regimen D was modified due to toxicities by reduction of cyclophosphamide to 55 mg/kg/day and methotrexate to 320 mg/kg.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…[13][14][15][16][17][18][19][20][21][22] The basic treatment schema consisted of five 21-to 28-day cycles of induction chemotherapy: cisplatin (3.5 mg/kg) on day 0, vincristine (0.05 mg/kg) on days 0, 8 and 15, cyclophosphamide (65 mg/kg) on days 1 and 2 and etoposide (4 mg/kg) on days 1 and 2 (Regimen A, HS I) with the addition of high-dose methotrexate (400 mg/kg) on day 3 for metastatic patients (HS II Regimen A2), or with two cycles replacing cisplatin and methotrexate by oral etoposide (1.67 mg/kg/day) on days 1-10 and oral temozolomide (6.5 mg/kg/day) on days 1-5 (HS III Regimen D or D2). During HS III, Regimen D was modified due to toxicities by reduction of cyclophosphamide to 55 mg/kg/day and methotrexate to 320 mg/kg.…”
Section: Methodsmentioning
confidence: 99%
“…These trials sought to improve patients' cure rate and quality of survival through avoidance or reduction of CNS irradiation by utilizing a single cycle of marrow-ablative chemotherapy with autologous hematopoietic rescue as consolidation following initial induction chemotherapy. [13][14][15][16][17][18][19][20][21][22] The goal of this present study was to examine changes in the rate of serious toxicities (grades III-V) associated with AuHCR in the first 100 days following transplant over the course of the 'Head Start' trials from 1991 to 2009.…”
Section: Introductionmentioning
confidence: 99%
“…Because of its rapid progression and its severe prognosis, front-line multimodal intensive treatment is the widest adopted therapeutic option [3,[6][7][8]. Recent and most successful studies consist, after surgery, with the goal of achieving gross tumor resection, intensive systemic and intrathecal chemotherapy, followed by highdose chemotherapy (HDCT) with autologous hemopoietic stem cells rescue [3,[6][7][8], and radiotherapy. The role of HDCT is still unclear because limited data are available.…”
Section: Discussionmentioning
confidence: 99%
“…The prognosis for patients with AT/RT is poor, with a mean overall survival less than 1 year [3]. Patients younger than 2 years or with metastatic disease at diagnosis carry a dismal prognosis, while patients presenting with older age, localized disease, and adequate surgery share a better outcome [5,6].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation